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Article history:
GABRB3 gene is a recently identified gene located in 15q12 chromosome and encodes
Received: 13 November 2019 for gamma-aminobutyric acid (GABA) receptor subunit beta-3 protein, which is linked
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to the GABAA receptor. The gene is believed to share a role in inhibitory GABAergic
synapses, GABA iron-gated channel function, and possible cellular response to
Online:
DOI 10.5001/omj.2021.27
histamine. The β3 subunit is expressed in cerebral grey matter, thalami, hippocampi,
and cerebellum, among other structures. Faulty GABRB3 function is linked to several
Keywords:
neurological disorders and clinical syndromes. However, the spectrum of such disorders
Receptors, GABA;
gamma-Aminobutyric Acid; is not yet well known. We present three case reports highlighting the potentially
Mutation; Phenotype.
expanding clinical phenotype and variable expression in children with mutated
GABRB3 gene.

T

he GABRB3 gene is a recently
identified gene in a locus known with
various clusters of major genes in the
long arm of chromosome 15.1 This
15q11-q13 locus is a known region of different
genomic DNA deletions and duplications related to
some neurodegenerative and neurodevelopmental
disorders including , for example, Angelman
syndrome and autism spectrum disorder (ASD).2,3
Several gamma-aminobutyric acid (GABA) genes
are mapped to the nearby 15q12 locus.4 It is believed
that any changes in the GABAergic signaling
pathway are likely to result in several neurological
disorders. However, the spectrum and extension of
such clinical implications are yet to be unraveled.
Our three reported cases do illustrate the likely wide
variation in clinical phenotype in heterozygous
GABRB3 mutations.

C A S E R E P O RT
Case one

A previously healthy male infant was thought to
have a normal neurodevelopmental profile till
the age of 20-month-old at presentation. He was
born at term after an uneventful pregnancy and
uncomplicated normal delivery. His family history
was negative for any neurological or developmental
disorders in close blood relatives. He was noted to
have several worrisome observations around the

*Corresponding author: drabboody@hotmail.com

age of 20 months old, including progressive loss of
consistent eye contact, consistently irritable mood
with inconsolable high pitch cry, and worsening
loss of prior vocabulary and speech abilities. He was
described as more clumsy and noted to have more
frequent falling than usual as he started walking
around the age of one-year-old. Multiple family
members noticed overall worsening with decreased
interaction with family members and usual
social cues. Because of the numerous concerning
observations, his primary care physician initiated an
urgent referral to the neurology specialist service.
Upon evaluation by neurology service, he was found
to be well-looking with no signs of acute illness.
However, he had multiple abnormal neurological
exam findings such as poor eye contact, irritable
mood, diffusely decreased axial and appendicular
tone, along with brisk deep tendon reflexes
throughout all extremities. No nystagmus, cranial
nerve palsies, striking abnormal facial features,
or neurocutaneous signs were noted. No joint
contractures or deformities were found. With this
concerning neurological decline and abnormal
physical exam, a brain magnetic resonance imaging
(MRI) with magnetic resonance spectroscopy was
completed and interpreted as an unremarkable study.
Basic and targeted metabolic screening was obtained,
including lysosomal, thyroid, amino acid, fatty acid,
and immune disorders, which were all found to be
negative. DNA genomic micro-array sequencing
test was then done and showed heterogeneous de
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novo p.L3101 pathogenic variant of GABRB3.
Although his variant was not previously reported, it
was thought to be pathological and likely represents
the underlying etiology of his clinical symptoms
and signs. The patient was started on an intensive
rehabilitation program. Interestingly, his response to
physical, occupational, and speech therapy services
were positive and remarkable, and he continues to
make developmental progress.

Case two

An 18-month-old female infant presented to the
emergency department for the first time with
likely a brief febrile seizure. She was a product
of an uneventful pregnancy, regular reassuring
prenatal care, and spontaneous vaginal delivery at
38 weeks estimated gestational age. She attained
all her motor and social developmental milestones
within the normal range expected timelines with no
regression. However, she was observed to have mild
expressive speech delay as she was able to only say
five to six words at the age of 18 months and could
not combine words. Her family history included a
cousin with childhood-onset epilepsy and another
cousin with febrile seizures. Upon presentation to
the emergency room, she had an apparent focal onset
for her seizure with lateralized versive eye gazing,
focal unilateral facial twitching, and unilateral
body shaking. She was febrile with some upper
respiratory symptoms but no other symptoms or
signs of serious or central nervous system infection.
Her exam was reassuring after recovering from the
postictal period, and no focal neurological signs
were elicited. Extensive infectious workup was
negative. During hospitalization, she had two more
similar seizures. Because of seizure recurrence and
onset focality, she was ultimately diagnosed with a
complex febrile seizure. She was temporarily started
on levetiracetam because of seizure recurrence with
anticipation of the need for only short-term course.
Her electroencephalogram (EEG) study was normal.
Her brain MRI demonstrated a borderline Chiari
1 malformation but was otherwise unremarkable
and showed no evidence of hippocampal sclerosis
or focal cortical dysplasia. Given the mild speech
delay background, atypical clinical course for
febrile seizures, and family history, genetic testing
was then considered. Chromosome microarray
revealed p.P54L heterozygous autosomal dominant
pathogenic variant of GABRB3. A diagnosis of

generalized epilepsy with febrile seizures plus
(GEFS+) was determined. Her seizures were wellcontrolled with levetiracetam and medication
weaning is planned.

Case three

This male patient was born full-term (40
weeks estimated gestational age) after a largely
uncomplicated pregnancy and delivery with no
neonatal resuscitation or critical care needs. He had
normal behavioral and developmental progress up to
near puberty age, and no major health comorbidities
were noted. With a rather acute history, he
presented at the age of 12 years old with an acute
mental status change in the form of sudden onset of
repeating certain phrases inappropriately outside the
situational context. Other interesting behaviors were
also observed, such as continuous scribbling and
walking around in circles. Mental state examination
revealed deficits in short-term memory and abstract
thinking. However, physical and neurological exams
were otherwise unremarkable. He was diagnosed
preliminarily with acute encephalopathy. Complete
blood count, chemistry profile, drug screening, and
basic metabolic profile were all within normal limits.
Head computed tomography scan was normal. As
a part of medical evaluation, EEG was requested
and showed near continuous spike and slow-wave
complexes consistent with non-convulsive status
epilepticus. Anti-seizure medications were initiated,
and he showed a good initial response to the
benzodiazepine trial with lorazepam and midazolam.
However, his seizures were difficult to control over
time, so detailed epilepsy evaluation, including
genetic studies, was pursued. Epilepsy expanded
panel was then obtained, which showed a p.R217C
heterozygous autosomal dominant pathogenic
variant of the GABRB3 gene. His seizures remain
difficult to control with standard anti-seizure drugs.
Although his neuroimaging studies did not suggest
any additional epilepsy risk, he is now undergoing
further epilepsy surgery evaluations.

DISCUSSION

Chromosome 15q11-13 is a complex genetic locus
that encloses three GABAA receptor subunit
(GABR) genes, GABRB3, GABRA5, and GABRG3.
GABRB3 gene encodes for a member of the ligandgated ionic channel protein, which is one of the
O man m e d J, vo l 3 6 , no 2, M ar c h 2021
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subunits of a multi-subunit chloride channel that
serves as the receptor for GABA, a major inhibitory
neurotransmitter of the mammalian central nervous
system.5 Usually, both the wild-type and mutant
β3 subunit-containing α1β3γ2 GABAA receptors
are attributed to impaired intracellular β3 subunit
processing. It is believed that the β3 subunit is
expressed in various neuromodulatory circuits in
the cerebral cortex, hippocampus, and thalamic
reticular nucleus, where they mediate phasic and
tonic inhibition.6 GABRB3 gene mutation disorders
continue to constitute a diagnostic challenge given
the wide spectrum of linked clinical features and
associated syndromes.7–10
The relationship between GABRB3 mutations
and traits of ASD has been studied in several
systemic reviews, but results seem to be conflicting.
Some studies have demonstrated that singlenucleotide polymorphisms (SNPs) in GABRB3
have a statistically significant predictor value for
development of ASD.11–13 However, expression of
GABRB3 in a cohort of patients with ASD seems
to be aberrant. A recent meta-analysis by Noroozi
et al,14 suggested that some GABRB3 variants are
not associated with increased risk of ASD. In fact,
there is some evidence that different SNPs of GABA
receptor B3, A5, and G3 subunit genes located
on chromosome 15q11-q13 are not associated
with the development of ASD in different ethnic
populations.15 Our first case testing showed a de
novo pathological p.L3101 variant in the GABRB3
gene. To our knowledge, this variant was never
reported before in a cohort of patients with ASD
and GABRB3 mutations.
The contribution of GABRB3 gene alterations to
increased risk for febrile seizures in children is still
not well understood. Across the spectrum of GEFS+,
GABRB3 mutations were found in a small group of
patients. Mutations in SCN1A or GABRG2 are better
studied in GEFS+ cohort of patients.16 In a recent
review by Møller et al,17 416 patients with febrile
seizures and early life epileptic encephalopathy were
screened, identifying 22 patients with heterozygous
mutations in GABRB3, including three probands
from multiplex families. At the severe end of the
clinical spectrum, GABRB3 mutations are thought
to be closely associated with early-onset epileptic
encephalopathy, although SCN8A and CDKL5
mutations are more prevalent.18 Some recent reports
suggest GABRB3 is a potential etiological substrate

for severe myoclonic epilepsy of infancy, also known
as Dravet syndrome.19 Our reported second patient
is thought to fit the diagnosis of GEFS+ as she
continues to progress developmentally so far. Her
overall clinical progress and good control of seizures
with low-dose levetiracetam make the possibility of
other epileptic encephalopathies less likely.
Whether there is a substantial correlation
between alterations in the GABRB3 gene and lower
seizure threshold is an actively debated topic in the
era of epilepsy epigenetics. The spectrum of possibly
linked epilepsy syndromes is expanding, from
more benign syndromes like childhood absence
epilepsy to epileptic spasms and Lennox Gastaut
syndrome. Recent studies suggested that impaired
receptor localization to synapses is a common
pathophysiological mechanism for GABRB3
mutations, although the extent of impairment may be
different among mutant subunits, leading to variable
epilepsy-related phenotypes.20,21 GABRB3 mutations
were also noted in children with unclassified epilepsy
along with other genetic alterations after more
utilization of epilepsy genetic panel testing. No
specific seizure classification has been described,
thus emphasizing the role of genetic heterogeneity.
Whether GABRB3 mutations can result in more
severe phenotype and refractory epilepsy is not yet
known. Our third reported patient is running a super
refractory epilepsy clinical course and is currently
under evaluation for possible epilepsy surgery
consideration. Our patient had non-convulsive status
epilepticus upon presentation, which has not been
reported in patients with GABRB3 alterations. A
recent review of the genetics of pediatric intractable
epilepsy did not consider GABRB3 among the
genetic mutations which are known to be associated
with difficult-to-treat epilepsy.22

C O N C LU S I O N

GABAA receptor β3 subunits are widely expressed
in the developing brain. Mutations in GABRB3
gene appear to have a wide spectrum of clinical
implications. We believe our three reported cases
will add to the available knowledge about variations
across both genotype and phenotype spectrum.
More reports of this type will ultimately improve
our understanding of how these genetic alterations
are being translated into clinical manifestations for a
wide range of neurological disorders, particularly in
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the era of improved access and evolution of available
genetic testing techniques and the whole future of
precision-based medical care.
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